IMV to Host Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac
January 24 2020 - 6:05AM
Business Wire
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage
biopharmaceutical company pioneering a novel class of
immunotherapies, today announced that it will host a key opinion
leader symposium on the role of survivin in cancer biology and
DPX-Survivac’s potential as a targeted immunotherapeutic agent
across a range of tumor types. The event will be held on Thursday,
February 27, 2020 from 8:30 – 10:00 a.m. ET in New York, NY.
The event will feature presentations by key opinion leaders,
including:
- Sally P. Wheatley, Ph.D., Assistant Professor, School of Life
Sciences, University of Nottingham;
- Jeannine Villella, D.O., FACOG, FACS, Chair of Gynecologic
Oncology, Department of Obstetrics and Gynecology, Lenox Hill
Hospital and NYU Winthrop Hospital; and
- Oliver Dorigo, M.D, Ph.D., Associate Professor of Obstetrics
and Gynecology, Stanford University Medical Center, Stanford
University Medical Center.
Additionally, IMV management will provide a corporate update,
including an overview of recent data from ongoing studies of
DPX-Survivac, which is currently being evaluated in three Phase 2
studies in advanced ovarian cancer, relapsed/refractory diffuse
large B-cell lymphoma and a basket of solid tumor indications.
Topline results are expected from all three studies in 1H20.
A live webcast of the event will be available under “Events,
Webcasts and Presentations” in the Investors section of IMV’s
website and will be available for replay approximately two hours
following the live event.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory approval of
DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory approvals. IMV
Inc. assumes no responsibility to update forward-looking statements
in this press release except as required by law. These
forward-looking statements involve known and unknown risks and
uncertainties and those risks and uncertainties include, but are
not limited to, our ability to access capital, the successful and
timely completion of clinical trials, the receipt of all regulatory
approvals and other risks detailed from time to time in our ongoing
quarterly filings and annual information form Investors are
cautioned not to rely on these forward-looking statements and are
encouraged to read IMV’s continuous disclosure documents, including
its current annual information form, as well as its audited annual
consolidated financial statements which are available on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov/edgar.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at generating
powerful new synthetic therapeutic capabilities. IMV’s lead
candidate, DPX-Survivac, is a T cell-activating immunotherapy that
combines the utility of the platform with a target: survivin. IMV
is currently assessing DPX-Survivac as a monotherapy in advanced
ovarian cancer, as well as a combination therapy in multiple
clinical studies with Merck. Connect at www.imv-inc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200124005092/en/
Investor Relations
Marc Jasmin, IMV Senior Director, Investor Relations O:
(902) 492-1819 ext : 1042 M: (514) 617-9481 E:
mjasmin@imv-inc.com
Josh Rappaport, Director, Stern IR O: (212) 362-1200 E:
josh.rappaport@sternir.com
Media
Mrs. Delphine Davan, IMV, Director of Communications M:
(514) 968-1046 E: ddavan@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024